Reata Pharmaceuticals, Inc. Class A

RETA

$115.62

-34.69% (1 year change)

Avg closing price

Price range

Market Cap

$3.22 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

Revenue

-

Total revenue in the last quarter.

Net Income

-

Net income is all revenues minus all expenses including taxes and interest in the last quarter.

Earnings per Share

$-10.73

Earnings per share is the amount of net income that is attributed to each single share outstanding.

Dividends per Share

-

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Price-Earnings Ratio

-10.51x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

EBIT

-

Earnings before interest expenses and taxes in the last quarter.

Employees

220

The number of full time employees.

Revenue & Earnings

Balance Sheet

Reata Pharmaceuticals, Inc. Class A

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Südhof, Jonathan M. Graff and J. Warren Huff on September 1, 2002 and is headquartered in Irving, TX.

News

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $RETA #RETA--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Reata Pharmaceuticals, Inc.

Business Wire Business Wire, 5 days ago
Ocular Pain Market : Global Growth, Opportunities, Industry Analysis & Forecast To 2027 | Leading Players- Reata Pharmaceuticals, Inc, Kala Pharmaceuticals

Ocular Pain Market : Global Growth, Opportunities, Industry Analysis & Forecast To 2027 | Leading Players- Reata Pharmaceuticals, Inc, Kala Pharmaceuticals

Global ocular pain market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing at a healthy CAGR in the above-mention...

OpenPR OpenPR, 12 days ago
Regal Entertainment parent to open all movie theaters by July

Regal Entertainment parent to open all movie theaters by July

Regal Entertainment parent Cineworld Group said Tuesday it will reopen select theaters at the end of the month in some of its markets. All 787 of the company’s theaters are expected to be up and ru...

New York Post New York Post, 4 months ago